ArticleNature2024
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of venetoclax plus azacitidine based regimens in the treatment of relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis.Annals of hematology · 2025Pooled it
- Article
- Immune and cellular determinants of response to HMA-venetoclax regimens in acute myeloid leukemia.HemaSphere · 2026Article
- Article
- Very Long Chain Fatty Acid Synthesis is a Targetable Dependency in RAS Pathway Mutant Leukemia.Blood cancer discovery · 2026Article
- Dynamic genetic and nongenetic RAS-pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.Blood · 2026Article
- A single-cell lens into the co-evolution of genotypes and phenotypes in cancer.Nature reviews. Cancer · 2026Review
- Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Venetoclax for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: Prospects, resistance mechanisms and management strategies.Clinical and translational medicine · 2026Review
- Article
- The KDM-family inhibitor JIB-04 sensitizes AML cells to venetoclax by inducing a ferroptosis-like phenotype.Blood neoplasia · 2026Article
- Controversies in the Management of AML in Older Patients: A Canadian Perspective.Current oncology (Toronto, Ont.) · 2026Review
- Specific FbioRxiv : the preprint server for biology · 2026Article
- Hypomethylating agents plus venetoclaxHaematologica · 2026Article
- From complexity to clarity: aging bone marrow niche in bone and blood regeneration and malignancy.Bone research · 2026Review
- Article
- Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics.Blood neoplasia · 2026Article
- Synergistic targeting of eIF4A-mediated translation initiation and apoptosis in acute myeloid leukemia.Blood neoplasia · 2026Article
- Sustained MYC overexpression drives myeloid differentiation block and acquisition of leukemic phenotypes.Experimental hematology · 2026Article
- Exploiting tumor lineage features for precision cancer therapy.Trends in cancer · 2026Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Junya Sango *Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0009-0001-8763-4270
Saul Carcamo *Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-1510-1045
Maria Sirenko *Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-7816-8071
Abhishek Maiti *Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hager MansourDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Gulay UlukayaDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Lewis E TomalinTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-4545-7138
Nataly Cruz-RodriguezDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Tiansu WangDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Malgorzata OlszewskaDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Emmanuel OlivierDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0001-9288-1746
Manon JaudDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Bettina NadorpDepartment of Medicine, Division of Precision Medicine, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0003-1974-8425
Benjamin KrogerDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0001-5675-9102
Feng HuDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9605-7594
Lewis SilvermanTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Stephen S ChungDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Elvin WagenblastDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-0709-2759
Ronan ChaligneMeyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0003-4332-3291
Ann-Kathrin EisfeldClara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.ORCID 0000-0001-6442-1419
Deniz DemirciogluDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0001-7857-0407
Dan A LandauMeyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Piro LitoDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2196-3503
Elli PapaemmanuilDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-1709-8983
Courtney D DiNardoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9003-0390
Dan HassonDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Marina KonoplevaDepartment of Medicine (Oncology), Albert Einstein College of Medicine, Bronx, NY, USA.ORCID 0000-0002-9347-2212
Eirini P PapapetrouDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. eirini.papapetrou@mssm.edu.ORCID 0000-0001-7002-417X
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3MConduits: Mount Sinai Health System Translational Science HubUL1TR004419 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rosalind J Wright · 2022 to 2026
$46.4MTHE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4MThe Role of Focal Oncogene Amplifications in Lung CancerP01CA129243 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Sohrab P Shah · 2007 to 2026
$31.2MMechanisms and therapeutic implications of human clonal hematopoiesis (CH) mutationsR01CA271331 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Eirini Papapetrou · 2022 to 2026
$3.3MImpact of mutational order on molecular mechanisms of oncogenesisR01CA260711 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Eirini Papapetrou · 2022 to 2026
$3.2MCharting the differentiation topology of SF3B1 mutated clonal hematopoiesis (CH) and myelodysplastic syndromes (MDS) via a multi-omics single-cell toolkitR01HL157387 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LANDAU, DAN · 2022 to 2025
$2.7MMechanisms and targeting of aberrant Gas activation in myeloid neoplasmsR01CA271418 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Eirini Papapetrou · 2023 to 2026
$2.7MThe role of inflammation in the regulation of immune response in acute myeloid leukemiaR01CA283574 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Iannis Aifantis, Ann-Kathrin Eisfeld · 2023 to 2026
$2.3MMechanisms of adaptation and resistance to emerging therapies for lung cancerR01CA279264 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Piro Lito · 2023 to 2026
$2.0MNCATS NIH HHS UL1 TR004419NCI NIH HHS F31 CA254130NCI NIH HHS P01 CA129243NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA196521NCI NIH HHS R01 CA235622NCI NIH HHS R01 CA260711NCI NIH HHS R01 CA271331NCI NIH HHS R01 CA271418NCI NIH HHS R01 CA279264NCI NIH HHS R01 CA283574NCI NIH HHS R33 CA267219NCI NIH HHS R37 CA273232NHLBI NIH HHS R01 HL157387NIH HHS S10 OD026880NIH HHS S10 OD030463
Abstract
Cancer driver mutations often show distinct temporal acquisition patterns, but the biological basis for this, if any, remains unknown. RAS mutations occur invariably late in the course of acute myeloid leukaemia, upon progression or relapsed/refractory disease
Indexed as
Antineoplastic AgentsBridged Bicyclo Compounds, HeterocyclicDrug Resistance, NeoplasmLeukemia, Myeloid, AcuteMutationras ProteinsSulfonamidesAnimalsCell LineageClone CellsFemaleGranulocytesHumansMiceMonocytesNeoplastic Stem CellsAntineoplastic AgentsBridged Bicyclo Compounds, HeterocyclicProto-Oncogene Proteins c-bcl-2ras ProteinsSulfonamidesvenetoclax
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.